Anti-Gingipain B (RgpB) Antibody

Mouse Monoclonal Antibody specific to Glutamate NMDA Receptor NR3A/B Subunit

Product Specifications

CAS Number

9007-83-4

Product Name Alternative

Arginine-gingipain B

Gene Name

PORGN

NCBI Gene ID

<a href="https://www.ncbi.nlm.nih.gov/gene/?term=PORGN">PORGN</a>

UniProt

Q51844

Host

Mouse

Reactivity

Poryphyromonas gingivalis

Immunogen

Arginine-gingipain B (RgpB) from Porphyromonas gingivalis.

Target Antigen

Gingipain B

Target

Gingipain B

Clonality

Monoclonal

Isotype

IgG1

Type

Antibody

Applications

IHC, IB

Purification Method

Purified by Protein G affinity chromatography

Concentration

Lot Specific

Dilution

Dilute in PBS or medium that is identical to that used in the assay system.

Format

Purified

Form

Liquid

Buffer

Phosphate Buffered Saline

Additionnal Information

Paraffin-embedded formalin-fixed AD hippocampus and gingival tissue from a patient with periodontal disease stained with #13925 and compared to non-AD control tissue and mouse IgG1 control (see Dominy et al. Science Advances 5 (1): eaau3333). <br> Detection of RgpB in P. gingivalis wild-type strain W83 whole cells (see Nguyen K-A et al. J Bacteriol 189: 833-843).

Storage Conditions

This antibody is stable for at least one (1) year at -20°C. Store in appropriate aliquots to avoid multiple freeze-thaw cycles.

Specificity

This antibody recognizes a unique epitope within the immunoglobulin (Ig)-like domain of arginine-gingipain (RgpB).

Formulation

PBS, pH 7.4

Buffer pH

pH 7.4

Target Background

Arginine-gingipain B (RgpB) is a cysteine protease produced exclusively by Porphyromonas gingivalis, and it plays a central role in the pathogenicity of P. gingivalis in periodontal disease. Over the last several years, a possible association between Alzheimer disease (AD) and chronic periodontitis has been suggested based on detection of P. gingivalis infiltration in autopsy specimens from the brains of people with AD in association with neurons, tau tangles, and beta-amyloid as well as in cerebrospinal fluid of individuals diagnosed with AD. Oral administration of a gingipain inhibitor to mice with established brain infection by P. gingivalis decreased the amount of P. gingivalis DNA in brain as well as the levels of beta-amyloid and tumor necrosis factor-α. Taken together, the data suggest that gingipain inhibitors might be an effective treatment of AD. Clinical trials of gingipain inhibitors are currently underway.